Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERICK HUMBERTO ALAYO

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1841454758
CMS profile
643595
Location
CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$30,409.29

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERICK HUMBERTO ALAYO

NPI 1841454758 · CMS profile ID 643595

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841454758?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERICK HUMBERTO ALAYO, NPI 1841454758, CMS profile ID 643595. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841454758?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ERICK HUMBERTO ALAYO, NPI 1841454758, CMS profile ID 643595. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841454758?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ERICK HUMBERTO ALAYO, NPI 1841454758, CMS profile ID 643595, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841454758?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $30,409.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–102 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $6.9101/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647742077 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.3001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684617439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30,409.29 102
PY2020 $9,293.48 90
PY2021 $23,809.13 143
PY2022 $20,315.95 119
PY2023 $10,863.35 48
PY2024 $4,864.99 59
PY2025 $1,537.45 41

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $160,010.37 32
PY2024 Principal investigator $309,795.57 107
PY2023 Principal investigator $428,608.15 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $1,129.95 12/16/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839968
Principal investigator 1 ABBVIE INC. $1,664.70 12/04/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202527560
Principal investigator 1 Eli Lilly and Company $13,500.00 11/14/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATE
AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187882026
Principal investigator 1 Ardelyx, Inc. $11,100.00 10/29/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults No dispute reported 06/30/2026 1247838732
Principal investigator 1 Bausch Health US, LLC $1,200.66 09/11/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839964
Principal investigator 1 ABBVIE INC. $7,060.05 09/03/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202507615
Principal investigator 1 ABBVIE INC. $6,968.42 08/26/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202505785
Principal investigator 1 Bausch Health US, LLC $2,718.68 08/08/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839961
Principal investigator 1 ABBVIE INC. $2,635.35 08/05/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202501316
Principal investigator 1 ABBVIE INC. $12,150.61 07/10/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202497822
Principal investigator 1 ABBVIE INC. $2,825.70 07/02/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202494013
Principal investigator 1 Genentech, Inc. $5,838.00 07/02/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211603576
Principal investigator 1 Ferring Pharmaceuticals AS $65.00 06/24/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242060718
Principal investigator 1 Bausch Health US, LLC $3,023.41 06/11/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839988
Principal investigator 1 Bausch Health US, LLC $373.62 06/05/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839984
Principal investigator 1 Bausch Health US, LLC $1,505.39 05/13/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839995
Principal investigator 1 ABBVIE INC. $7,893.60 05/07/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202482763
Principal investigator 1 ABBVIE INC. $7,331.27 04/10/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202475981
Principal investigator 1 ABBVIE INC. $3,000.00 04/08/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202475009
Principal investigator 1 Bausch Health US, LLC $1,812.18 04/07/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224840001
Principal investigator 1 ABBVIE INC. $1,567.50 04/03/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202473475
Principal investigator 1 Bausch Health US, LLC $1,438.56 04/01/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839991
Principal investigator 1 Bausch Health US, LLC $373.62 03/11/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839971
Principal investigator 1 ABBVIE INC. $1,333.20 03/07/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202460948
Principal investigator 1 Bausch Health US, LLC $1,897.72 03/05/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839975
Principal investigator 1 Genentech, Inc. $13,512.00 03/05/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211603557
Principal investigator 1 ABBVIE INC. $11,968.80 02/06/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202447440
Principal investigator 1 ABBVIE INC. $1,000.00 02/05/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202444350
Principal investigator 1 Genentech, Inc. $3,336.00 01/31/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211603567
Principal investigator 1 Genentech, Inc. $12,510.00 01/29/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211603571
Principal investigator 1 Genentech, Inc. $14,178.00 01/14/2025 Non-covered Recipient Entity
ERICK H ALAYO MEDICAL CORPORATION
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211603562
Principal investigator 1 Bausch Health US, LLC $3,098.38 01/07/2025 Non-covered Recipient Entity
Erick H. Alayo Medical Corporation
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224839980